Sign in
Knowstox

Fundamentals snapshot

TriSalus Life Sciences, Inc.

TLSI · NGM · Healthcare · Medical Devices

Current price

$3.63

52-week range

$2.20 - $7.95

Market cap

$223.52M

One-glance verdict

Not enough data

Fair value unavailable

Not enough cash-flow history to value this one with our method.

Balance sheet

Healthy

-4.86x Concerning

Net cash $11.86M. Interest coverage shows how many times profit covers the interest bill.

What stands out

0 Rewards 0 Risks

0 rewards · 0 risks

Highlights are unavailable right now.

What this company does

TriSalus Life Sciences, Inc.

TriSalus Life Sciences develops special ways to deliver drugs and new cancer treatments, mainly for hard-to-treat liver and pancreatic cancers in the U.S. Their main product is a system that helps deliver medicine more effectively during procedures for liver cancer, and they are also testing a new drug to help the body fight certain cancers. This matters because they are trying to give patients with these serious diseases better options and improve their chances of recovery.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Free cash flow by quarter (oldest to newest)
FY2024 Q3 $-11.02M FY2024 Q4 $-5.76M FY2025 Q1 $-5.25M FY2025 Q2 $-7.41M FY2025 Q3 $-3.92M FY2025 Q4 $-2.52M FY2026 Q1 $-6.62M FY2026 Q2 $-10.21M
Revenue $11.41M
Net income $-9.19M
Diluted EPS -0.16
Operating cash flow $-10.13M
Free cash flow $-10.21M
Revenue $8.90M
Net income $1.54M
Diluted EPS 0.03
Operating cash flow $-6.48M
Free cash flow $-6.62M
Revenue $13.21M
Net income $-9.75M
Diluted EPS -0.22
Operating cash flow $-2.48M
Free cash flow $-2.52M
Revenue $11.57M
Net income $-10.81M
Diluted EPS -0.96
Operating cash flow $-3.71M
Free cash flow $-3.92M
Revenue $11.21M
Net income $-8.29M
Diluted EPS -0.27
Operating cash flow $-7.32M
Free cash flow $-7.41M
Revenue $9.17M
Net income $-10.38M
Diluted EPS -0.39
Operating cash flow $-4.50M
Free cash flow $-5.25M
Revenue $8.26M
Net income $-10.10M
Diluted EPS -0.38
Operating cash flow $-5.71M
Free cash flow $-5.76M
Revenue $7.35M
Net income $-2.40M
Diluted EPS -0.12
Operating cash flow $-10.85M
Free cash flow $-11.02M

Is it cheap or expensive?

Fair value — vs current price $3.63

We couldn't calculate a fair value right now.

lower confidence

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Is it drowning in debt?

Healthy

Net cash $11.9M - more cash than debt. Interest coverage -4.9x.

Net debt $-11.86M
Interest coverage -4.86x

TriSalus Life Sciences, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.

Healthy
Worse cushion Baseline Better cushion
TLSI BASELINE TriSalus Life Sciences, Inc.

Total debt $34.43M Interest coverage -4.86x This is the baseline the peer rows are being compared against.

-4.86x
PRCT PROCEPT BioRobotics Corporation

Total debt $77.50M Interest coverage -28.96x Neither company has much profit cushion over interest right now.

-28.96x
ENOV Enovis Corporation

Total debt $1.37B Interest coverage -0.54x Neither company has much profit cushion over interest right now.

-0.54x
IART Integra LifeSciences Holdings Corporation

Total debt $2.05B Interest coverage 0.21x This peer still has a real interest-payment cushion, while TLSI does not.

0.21x
SIBN SI-BONE, Inc.

Total debt $42.80M Interest coverage -8.50x Neither company has much profit cushion over interest right now.

-8.50x

What you should know

The case for and against TLSI

0 Rewards 0 Risks

Rewards

Risks

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
—
Forward P/E
-14.52x
P/B
33.93x
P/S
4.96x
EV/EBITDA
-7.62x
PEG ratio
—

Profitability

How much profit each dollar creates

Gross margin
85.8%
Operating margin
-86.0%
Net margin
-62.6%
ROE
—
ROA
-36.8%

Health

Liquidity and balance-sheet strength

Debt / equity
5.26x
Current ratio
5.35x
Quick ratio
4.72x
Total debt
$34.43M
Total cash
$46.29M

Growth

How the business has been compounding

Revenue TTM
$45.08M
Revenue 5Y CAGR
56.2%
EPS TTM
-1.22
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-22.80M
Free CF TTM
$-18.93M
FCF margin
-42.0%

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
—
Last ex-div date
—